Full-Time

Senior District Business Manager

Neuroscience, Cobenfy

Confirmed live in the last 24 hours

Deadline 8/4/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

No salary listed

Expert

Company Historically Provides H1B Sponsorship

Knoxville, TN, USA + 3 more

More locations: Nashville, TN, USA | Memphis, TN, USA | Chattanooga, TN, USA

Field-based role requiring 4 days in the field with Therapeutic Area Specialists (TASs).

Category
Strategic Account Management
Sales & Account Management
Requirements
  • Bachelor’s degree or equivalent with a minimum of 10 years of pharmaceutical industry experience or other related industry experience.
  • Understanding of Neuropsychiatry environment, call points, and industry trends preferred.
  • 5 or more years of prior experience as a District Business Manager in Pharmaceutical Sales, or equivalent experience in leading and managing high-performing teams is strongly preferred.
  • Pharma experience is strongly preferred, including an understanding of reimbursement processes, access, and distribution environment.
  • Proven track record of inspiring and leading teams to meet or exceed expectations and goals.
  • Proven successful track record of selecting, developing, and retaining talented individuals.
  • Previous experience that has required the use of analytical skills, selling skills, development of strong business acumen, and working knowledge of the pharmaceutical value chain.
  • As this position requires the operation of a Company-provided vehicle, offers of employment are contingent upon the candidate meeting the requirements of 'Qualified Driver,' as determined by the Company in its sole discretion, including but not limited to the following: 1) at least 21 years of age; 2) a driver’s license in good standing issued by your state of residence; and 3) a driving risk level deemed acceptable by the Company.
Responsibilities
  • Focused in-role coaching and developing of TASs
  • Sourcing, recruiting, onboarding and training Therapeutic Area Specialists to support launch of COBENFY.
  • Coach TASs on specific competencies and learning objectives (e.g., scientific agility, customer/commercial mindset, change agility & teamwork/enterprise mindset). DBMs will conduct selected ride-alongs with TASs for the most important HCPs as relevant, according to coaching plan.
  • Ownership for TASs learning journey and accountable for ensuring continuous improvement in core skills and behavior (e.g., scientific agility, patient mindset, digital agility, analytical mindset).
  • Champion adoption of new capabilities (e.g., CE^3 analytics, content personalization)
  • Understand and role model new capabilities and tools e.g., sharing knowledge, information, insights and experiences with new tools with the TAS team.
  • Effectively coach TASs on how to appropriately leverage CE^3 insights to guide call planning and call preparation.
  • Regularly convene field team to exchange experiences, collect feedback, proactively coach on change leadership, and encourage adoption of capabilities and new ways of working.
  • Execute strategic planning activities (e.g., promo program planning, budget planning, and prioritization at HCP level).
  • Engage with relevant insights to prioritize accounts and develop strategies for key accounts.
  • Ensure continues customer experience improvement.
  • Lead financial and program planning for district.
  • Comply with all laws, regulations, and policies that govern the conduct of BMS.
Desired Qualifications
  • Coaching mindset: Understands TASs learning journey and takes responsibility for ensuring continuous improvement of TASs skills. Ability to coach TASs in core competencies: (e.g., scientific agility, customer experience, patient centricity and mindset, digital agility, analytical mindset).
  • Customer/commercial mindset: Demonstrated ability to drive business results. Experience identifying, engaging, and cultivating credibility with customer across the patient care journey. Demonstrated account management skills and problem-solving mentality. Understands the flow of patients through practice and can customize engagement and deliver tailored messages. Demonstrated resourcefulness and ability to connect with customers.
  • Scientific agility: Expertise in TA. Excellent communication and presentation skills to articulate scientific and clinical data in an easy-to-understand manner to help HCPs best serve their patients. Has a strong learning mindset and passion for science. Prioritizes staying current with the latest data.
  • Change agility: Enthusiasm to adopt and champion new ways of working. Demonstrates a strong sense of learning agility. Seeks out and learns from unfamiliar experiences, and then applies those lessons to achieve better results in subsequent situations.
  • Analytical mindset: Ability to use data insights to inform engagement. Ability to run more focused strategic planning. Digital mindset – adept at using digital tools.
  • Teamwork/Enterprise mindset: Ability to lead across the matrix. Strong business acumen to understand and analyze business and market drivers and develop, execute, and adjust business plans. Track record of balancing individual drive and collaborative attitude.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, particularly in oncology, immunology, and cardiovascular health. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high quality and safety standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, as well as its commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with BioNTech enhances BMS's oncology portfolio against competitors like Merck.
  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • $40 billion US investment shows BMS's commitment to long-term growth and innovation.

What critics are saying

  • Heavy reliance on real-world data may affect drug approval if data quality falters.
  • $11.1 billion BioNTech partnership could strain finances if results are underwhelming.
  • Recent layoffs may impact operational efficiency and employee morale at BMS.

What makes Bristol Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company integrates real-world data to enhance drug development and patient outcomes.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.

Hit Consultant
Jun 10th, 2025
From Raw Records To Real-Time Insights: Climbing Pharma’S Real-World Data Maturity Curve

Viraj Narayanan, CEO at Cornerstone AI Daniel Lane, Head of RWD Strategy & Operations at Bristol Myers SquibbReal-world data (RWD) has become the pharmaceutical industry’s most promising yet challenging frontier. While companies have long recognized its potential to complement clinical trials and deepen patient outcome insights, many still struggle to fully realize its value.We’ve seen firsthand, from early discovery to market authorization to post-launch evidence generation, that extracting meaningful value from RWD requires more than just data acquisition. It demands a consistent, scalable, and repeatable approach to data quality, as well as a strategic roadmap that moves an organization from minimal use of RWD to a position of true leadership. This journey isn’t simple, but for those committed to navigating it, the competitive advantages are substantial. And, importantly, RWD holds the potential to help bring lifesaving and life-changing medications to market faster and safer than ever before.From Data Collection to MaturityPharma’s growing reliance on RWD has encouraged an influx of partnerships with data aggregators, medical institutions, and digital health platforms. Yet, not all companies are at the same level of maturity in using that data effectively

Devdiscourse
Jun 2nd, 2025
Reuters Health News Summary

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

The Motley Fool
Jun 2nd, 2025
Why BioNTech Stock Soared Today

BioNTech and Bristol Myers Squibb are teaming up to develop a new cancer drug, BNT327.